DKK169.40
0.76% yesterday
Copenhagen, Jun 27, 04:59 pm CET
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Bavarian Nordic Stock price

DKK169.40
-3.55 2.05% 1M
-24.75 12.75% 6M
-19.95 10.54% YTD
-17.75 9.48% 1Y
-54.70 24.41% 3Y
-14.60 7.93% 5Y
-144.10 45.96% 10Y
-376.60 68.97% 20Y
Copenhagen, Closing price Fri, Jun 27 2025
-1.30 0.76%
ISIN
DK0015998017
Symbol
BAVA
Sector
Industry

Key metrics

Basic
Market capitalization
DKK13.4b
Enterprise Value
DKK12.3b
Net debt
DKK-1.1b
Cash
DKK1.2b
Shares outstanding
77.8m
Valuation (TTM | estimate)
P/E
10.39 | 9.73
P/S
2.16 | 2.07
EV/Sales
1.98 | 1.89
EV/FCF
negative
P/B
1.14
Financial Health
Equity Ratio
79.19%
Return on Equity
8.66%
ROCE
11.30%
ROIC
12.15%
Debt/Equity
0.01
Financials (TTM | estimate)
Revenue
DKK6.2b | DKK6.5b
EBITDA
DKK2.0b | DKK2.1b
EBIT
DKK1.3b
Net Income
DKK1.3b | DKK1.4b
Free Cash Flow
DKK-921.1m
Growth (TTM | estimate)
Revenue
-6.18% | 13.83%
EBITDA
-7.13% | 105.25%
EBIT
32.24%
Net Income
34.22% | 37.15%
Free Cash Flow
-189.61%
Margin (TTM | estimate)
Gross
51.90%
EBITDA
32.11% | 32.13%
EBIT
21.30%
Net
21.20% | 20.82%
Free Cash Flow
-14.78%
More
EPS
DKK16.30
FCF per Share
DKK-11.83
Short interest
-
Employees
1.61k
Rev per Employee
DKK3.56m
Show more

Is Bavarian Nordic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Bavarian Nordic Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Bavarian Nordic forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Bavarian Nordic forecast:

Buy
82%
Hold
18%

Financial data from Bavarian Nordic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6,231 6,231
6% 6%
100%
- Direct Costs 2,997 2,997
15% 15%
48%
3,234 3,234
20% 20%
52%
- Selling and Administrative Expenses 1,057 1,057
23% 23%
17%
- Research and Development Expense 850 850
45% 45%
14%
2,001 2,001
7% 7%
32%
- Depreciation and Amortization 673 673
41% 41%
11%
EBIT (Operating Income) EBIT 1,328 1,328
32% 32%
21%
Net Profit 1,321 1,321
34% 34%
21%

In millions DKK.

Don't miss a Thing! We will send you all news about Bavarian Nordic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Head office Denmark
CEO Paul Chaplin
Employees 1,605
Founded 1992
Website www.bavarian-nordic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today